Ignite Creation Date:
2024-05-06 @ 3:32 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04669496
Status:
RECRUITING
Last Update Posted:
2021-07-07
First Post:
2020-12-14
Brief Title:
Phase II-III Clinical Trial of PD1 Antibody Toripalimab Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Organization Data
Organization:
Shanghai Zhongshan Hospital
Class:
OTHER
Study ID:
ZS--ICC-NA
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shanghai Zhongshan Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Shenzhen University General Hospital | OTHER |
| Xinhua Hospital Shanghai Jiao Tong University School of Medicine | OTHER |
| Shanghai 6th Peoples Hospital | OTHER |
| Shanghai Public Health Clinical Center | OTHER_GOV |
| RenJi Hospital | OTHER |